Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 9/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | TEK | Q02763 | 1/20 | 0.44 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1016964 | 0.92 | SERPINE1 (0.51) | KLK7KDRTEKSERPINE1AURKB | |
| SCHEMBL1014903 | 0.86 | SCD (0.40) | KLK7SERPINE1RXFP1MAPK1MEN1 | |
| SCHEMBL1016204 | 0.85 | SERPINE1 (0.38) | KDRSERPINE1RXFP1MEN1KMT2A | |
| SCHEMBL1016339 | 0.84 | CNR1 (0.53) | KDRSERPINE1MAPK1MEN1KMT2A | |
| SCHEMBL1015635 | 0.84 | CNR1 (0.51) | SERPINE1MEN1KMT2AKDM4E | |
| SCHEMBL1012911 | 0.84 | MEN1 (0.44) | KDRSERPINE1MAPK1MEN1KMT2A | |
| SCHEMBL1015837 | 0.82 | CNR1 (0.51) | SERPINE1MAPK1MEN1KMT2AKDM4E | |
| SCHEMBL1015662 | 0.81 | SERPINE1 (0.64) | KLK7SERPINE1MAPK1MEN1KMT2A | |
| SCHEMBL1013298 | 0.81 | CNR1 (0.53) | KLK7SERPINE1RXFP1MEN1KMT2A | |
| SCHEMBL1015897 | 0.80 | EDNRA (0.49) | SERPINE1MEN1KMT2AKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415479-B2 | Inhibitor of plasminogen activator inhibitor-1 | RENASCIENCE CO., LTD. (JP) | 2013-04-09 | — | — | US | disclosed |
| US-20110112140-A1 | INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 | RENASCIENCE CO., LTD. (JP) | 2011-05-12 | — | — | US | disclosed |
| EP-2272822-A1 | INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 | Renascience CO., LTD. (JP) | 2011-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112140-A1 | INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 | SERPINE1, SERPINB1, SERPINC1 | KLK7 295/4885KDR 4155/4885TEK 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.